Ventricular fibrillation associated with use of synephrine containing dietary supplement

Military Medicine

Volumn 174, Issue 12, 2009, Pages 1313-1319

  Stephensen, Travis A ^a   Sarlay Jr , Robert ^a  

^a AP 96278 2060   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

OXEDRINE;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DIET SUPPLEMENTATION; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLE FIBRILLATION; HUMAN; RESUSCITATION; SOLDIER;

ADULT; CARDIOPULMONARY RESUSCITATION; DIETARY SUPPLEMENTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MILITARY PERSONNEL; SYNEPHRINE; VENTRICULAR FIBRILLATION;

EID: 77449089430     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED-D-01-5009     Document Type: Article

References (38)

1. Hegal KM, Carroll MD, Ogden DL, Johnson CL: Prevalence and trends in obesity among US adults. 1999200. JAMA 2002;288:1723-7.
2. DeFraites R: Diagnosis of overweight/obesily. active component. U. S. Armed Forces, 1998-2008. MSMR2009;16:2-7.
3. Ayyad C, Andersen T: Long-term efficacy of dietary treatment of obesity: systematic review of studies published between 1931 and 1999. Obes Rev 2000: 1: 113-9.
4. World Health Organization: WHO Consultation on Obesity. Geneva, Switzerland. WHO. 1997.
5. Blanck HM, Serdula MK, et al: Use of nonprescription dietary supplements for weight loss is common among Americans. J Am Diet Assoc 2007: 107: 441-7.
6. Institute of Medicine: Use of dietary supplements by military personnel, pp 383-419. Washington, DC, The National Archives Press, 2008.
7. Food and Drug Administration. Department of Health and Human Services: Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Fed Regist 2004;69(28):6787-854.
8. Schumer C, Sweeney JE: New US ephedra ban doesn't go far enoughephedra copycats dodge ban and 15 ephedra clones already on sale in NY. Press release and survey results from Senator Charles E. Schumer. 2004. Available at http://schumer.senate.gov/new-website/record.cfm? id=265310&: accessed October 20, 2009.
9. Blumenthal M: Bitter Orange Peel and Synephrine. WholeFoods, American Botanical Council. March 2005.
10. Bouchard NC, Howland MA, et al: Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clin Proc 2005;80(4):541-5.
11. Pellati F, Benvenuti S, Melegarai M, et al: Determination of adrenergic agonists from extracts and herbal products of Citrus aurantium L. var. amara by LC. J Pharm Biomed Anal 2002;29:1113-9.
12. Starke K: A history of Naunyn-Schmiedeberg's archives of pharmacology. Naunyn Schmiedebergs Arch Pharmacol 1998: 358: 1-109.
13. Brown CM, McGrath JC, et al: Activities of octopamine and synephrine stereoisomers on alpha-adrenoceptors. Br J Pharmacol 1988;93:417-29.
14. Preuss HG, DiFernando D, et al: Citrus aurantium as a thermogenic, weight-reduction replacement for ephedra: an overview. J Med 2002;33 (1-4) : 247-64.
15. Jordan R, Midgley JM, et al: Beta-adrenergic activities of octopamine and synephrine stereoisomers on guinea-pig atria and trachea. J Pharm Pharmacol 1987: 39: 752-4.
16. Haller CA, Benowitz NL: Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000: 343: 1833-8.
17. Arch JR: Beta (3) -adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 2002;440:99-107.
18. Weyer C, Gautier JF, et al: Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes-an update. Diabetes Metab 1999;25:11-21.
19. Carpene C, Galitzky J, et al: Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn Schmiedebergs Arch Pharmacol 1999;359(4):310-21.
20. 2-adrenoceptors in conscious dogs. Am J Physiol 1987;253 (2 Pt 2) : H388-93.
21. 2-receptors mediating vasoconstriction. J Vet Pharmacol Ther 1997;20(4):308-17.
22. 2 adrenoceptors in the post laparotomy intestinal motor disturbances in the rat. Gut 1987;28(8):955-9.
23. Bell A, Dorsch KD, McCreary DR, et al: A look at nutritional supplement use in adolescents. J Adolesc Health 2004;34:50-16.
24. Haaz S, Fontaine KR, et al: Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Rev 2006;7:79-88.
25. Bent S, Padula A, Neuhaaus J: Safety and efficacy of Citrus aurantium for weight loss. Am J Cardiol 2004;94:1359-61.
26. Calapai G, Firenauoli F, et al: Antiobesity and cardiovascular toxic effects of Citrus aurantium extracts in the rat; a preliminary report. Fitoterapia 1999:70:586-92.
27. Haller CA, Benowitz NL, Jacob P III: Hemodynamic effects of ephedra-free weight-loss supplements in humans. Am J Med 2005;118:998-1003.
28. Nasir JM, Durning SJ, et al: Exercise-induced syncope associated with QT prolongation and ephedra-free Xenadrine. Mayo Clin Proc 2004: 79: 1059-62.
29. Nykamp DL, Fackih MN, et al: Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. Ann Pharmacother 2004: 38: 812-6.
30. Gange GA, Madias C, et al: Variant angina associated with bitter orange in a dietary supplement. Mayo Clin Proc 2006;81(4):545-8.
31. Sultan S, Spector J, et al: Ischemic colitis associated with use of a bitter orange containing dietary weight-loss supplement. Mayo Clin Proc 2006;81(12):1630-1.
32. Jordan S, Murty M, Pilon K: Products containing bitter orange or synephrine: suspected cardiovascular adverse reactions. CMAJ 2004: 171: 993-4.
33. Cooper DW, Carpenter M, et al: Fetal and maternal effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. Anesthesiology 2002;97:1582-90.
34. Lee A, Ngan KWD, et al: A quantitative, systematic review of randomized controlled trials of ephedrine versus phenylephrine for the management of hypotension during spinal anesthesia for cesarean delivery. Anesth Analg 2002;94:920-6.
35. Sahu D, Kothari D, et al: Phenylephrine, ephedrine and rnephentermine for spinal hypotension. Indian Journal of Anaesthesia 2003;47:125-8.
36. Food and Drug Administration: Overview of dietary supplements. January 3, 2001. San Francisco. Center for Food Safety and Applied Nutrition, 2001. Available at http://www.fda.gov/Hood/DietarySupplements/ConsumerInformation/ ucm110417.htm; accessed October 20, 2009.
37. Oxedrine. Clarke's Analysis of Drugs and Poisons, 3rd ed. Edited by Moffat AC, Osselton MD, Widdop B. London. Pharmaceutical Press. Electronic Version. 2004.
38. Naranjo CA, Buster U, Sellers EM, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981: 30: 239-45.